Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603669.SS Stock Summary
Top 10 Correlated ETFs
603669.SS
In the News
603669.SS Financial details
Company Rating
Neutral
Market Cap
3.01B
Income
-222.86M
Revenue
188.72M
Book val./share
1.24
Cash/share
1.08
Dividend
-
Dividend %
-
Employees
497
Optionable
No
Shortable
Yes
Earnings
20 Oct 2023
P/E
-20.85
Forward P/E
-
PEG
0.5
P/S
21.18
P/B
4.49
P/C
3.7
P/FCF
-20.36
Quick Ratio
2.99
Current Ratio
3.24
Debt / Equity
0.63
LT Debt / Equity
0.42
-
-
EPS (TTM)
-0.28
EPS next Y
-
EPS next Q
-
EPS this Y
-377.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-29.57%
Revenue Q/Q
-4.73%
EPS Q/Q
-47.21%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-20%
Inst Own
-
Inst Trans
-
ROA
-12%
ROE
-21%
ROC
-0.15%
Gross Margin
40%
Oper. Margin
-114%
Profit Margin
-118%
Payout
-2%
Shs Outstand
717.62M
Shs Float
328.15M
-
-
-
-
Target Price
-
52W Range
2.94-6.07
52W High
-33.33%
52W Low
+100%
RSI
44
Rel Volume
1.04
Avg Volume
7.13M
Volume
7.43M
Perf Week
-7.19%
Perf Month
22.32%
Perf Quarter
-
Perf Half Y
-22.63%
-
-
-
-
Beta
0.248383
-
-
Volatility
0.16%, 0.26%
Prev Close
2.3%
Price
4
Change
-0.25%
603669.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.35 | 2.29 | 1.38 | 1.03 | 0.37 | |
Net income per share | 0.26 | 0.28 | 0.22 | 0.09 | -0.25 | |
Operating cash flow per share | 0.26 | 0.33 | 0.17 | 0.18 | -0.08 | |
Free cash flow per share | 0.02 | 0.32 | 0.09 | 0.1 | -0.14 | |
Cash per share | 0.98 | 1.21 | 2.4 | 2.19 | 1.23 | |
Book value per share | 1.94 | 1.84 | 2.03 | 2.04 | 1.45 | |
Tangible book value per share | 1.87 | 1.77 | 1.89 | 1.86 | 1.3 | |
Share holders equity per share | 1.94 | 1.84 | 2.03 | 2.04 | 1.45 | |
Interest debt per share | 0.56 | 0.37 | 1.5 | 1.35 | 0.8 | |
Market cap | 3.63B | 3.74B | 6.27B | 7.15B | 4.49B | |
Enterprise value | 3.32B | 3.48B | 5.78B | 7.11B | 4.54B | |
P/E ratio | 19.88 | 18.55 | 39.18 | 108.44 | -22.96 | |
Price to sales ratio | 2.18 | 2.29 | 6.27 | 9.65 | 15.54 | |
POCF ratio | 19.54 | 15.88 | 49.46 | 55.61 | -67.73 | |
PFCF ratio | 298.27 | 16.64 | 96.69 | 96.99 | -41.16 | |
P/B Ratio | 2.64 | 2.85 | 4.24 | 4.9 | 3.96 | |
PTB ratio | 2.64 | 2.85 | 4.24 | 4.9 | 3.96 | |
EV to sales | 1.99 | 2.13 | 5.78 | 9.6 | 15.69 | |
Enterprise value over EBITDA | 13.77 | 12.73 | 24.38 | 51.82 | -37.42 | |
EV to operating cash flow | 17.84 | 14.77 | 45.6 | 55.32 | -68.4 | |
EV to free cash flow | 272.29 | 15.48 | 89.15 | 96.47 | -41.56 | |
Earnings yield | 0.05 | 0.05 | 0.03 | 0.01 | -0.04 | |
Free cash flow yield | 0 | 0.06 | 0.01 | 0.01 | -0.02 | |
Debt to equity | 0.29 | 0.19 | 0.73 | 0.65 | 0.55 | |
Debt to assets | 0.19 | 0.13 | 0.4 | 0.38 | 0.33 | |
Net debt to EBITDA | -1.31 | -0.95 | -2.06 | -0.27 | -0.36 | |
Current ratio | 2.63 | 3.06 | 2.79 | 2.76 | 3.74 | |
Interest coverage | 94.22 | 16.38 | 16.06 | 4.59 | -28.14 | |
Income quality | 1.02 | 1.17 | 0.79 | 1.95 | 0.34 | |
Dividend Yield | 0.03 | 0.07 | 0.02 | 0.02 | 0.02 | |
Payout ratio | 0.58 | 1.39 | 0.71 | 2.42 | -0.41 | |
Sales general and administrative to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.05 | |
Research and developement to revenue | 0.01 | 0.02 | 0.02 | 0.03 | 0.11 | |
Intangibles to total assets | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | |
Capex to operating cash flow | -0.93 | -0.05 | -0.49 | -0.43 | 0.65 | |
Capex to revenue | -0.1 | -0.01 | -0.06 | -0.07 | -0.15 | |
Capex to depreciation | -5.85 | -0.31 | -1.65 | -1.27 | -0.95 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.02 | |
Graham number | 3.35 | 3.42 | 3.17 | 2.06 | 2.86 | |
ROIC | 0.11 | 0.13 | 0.06 | 0.03 | -0.1 | |
Return on tangible assets | 0.09 | 0.11 | 0.06 | 0.03 | -0.11 | |
Graham Net | 0.27 | 0.7 | 0.96 | 0.91 | 0.44 | |
Working capital | 822.09M | 825.36M | 1.31B | 1.14B | 829.62M | |
Tangible asset value | 1.33B | 1.26B | 1.38B | 1.33B | 1.02B | |
Net current asset value | 636.49M | 626.46M | 802.48M | 732.75M | 411.72M | |
Invested capital | 0.29 | 0.19 | 0.73 | 0.65 | 0.55 | |
Average receivables | 206.6M | 223.83M | 226.23M | 178.72M | 127.95M | |
Average payables | 138M | 138M | 94.9M | 58.8M | 64.28M | |
Average inventory | 80.42M | 79.55M | 79.44M | 60.37M | 50.4M | |
Days sales outstanding | 43.9 | 55.11 | 74.97 | 74.85 | 131.32 | |
Days payables outstanding | 256.04 | 219.67 | 130.13 | 148.46 | 260.5 | |
Days of inventory on hand | 125.23 | 146.89 | 161.95 | 123.51 | 192.62 | |
Receivables turnover | 8.31 | 6.62 | 4.87 | 4.88 | 2.78 | |
Payables turnover | 1.43 | 1.66 | 2.8 | 2.46 | 1.4 | |
Inventory turnover | 2.91 | 2.48 | 2.25 | 2.96 | 1.89 | |
ROE | 0.13 | 0.15 | 0.11 | 0.05 | -0.17 | |
Capex per share | -0.24 | -0.02 | -0.09 | -0.08 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.07 | 0.05 | 0.1 | 0.05 | 0.05 | |
Net income per share | -0.15 | -0.16 | -0.03 | -0.06 | -0.03 | |
Operating cash flow per share | -0.15 | -0.16 | -0.03 | -0.01 | 0.01 | |
Free cash flow per share | -0.17 | -0.19 | -0.05 | -0.01 | 0 | |
Cash per share | 1.37 | 1.23 | 1.29 | 1.18 | 1.08 | |
Book value per share | 1.88 | 1.45 | 1.45 | 1.39 | 1.24 | |
Tangible book value per share | 1.7 | 1.3 | 1.3 | 1.24 | 1.11 | |
Share holders equity per share | 1.88 | 1.45 | 1.45 | 1.39 | 1.24 | |
Interest debt per share | 0.75 | 0.79 | 0.89 | 0.85 | 0.79 | |
Market cap | 3.76B | 4.49B | 4.23B | 3.56B | 4.31B | |
Enterprise value | 3.74B | 4.54B | 4.4B | 3.78B | 4.49B | |
P/E ratio | -8.91 | -8.9 | -46 | -19.07 | -40.07 | |
Price to sales ratio | 73.74 | 118.1 | 57.71 | 89.95 | 114.07 | |
POCF ratio | -35.65 | -35.59 | -184 | -462.36 | 609.87 | |
PFCF ratio | -32.53 | -29.49 | -113.29 | -374.97 | 1.89K | |
P/B Ratio | 2.91 | 3.96 | 3.8 | 3.36 | 4.16 | |
PTB ratio | 2.91 | 3.96 | 3.8 | 3.36 | 4.16 | |
EV to sales | 73.45 | 119.26 | 60.08 | 95.47 | 118.84 | |
Enterprise value over EBITDA | -34.28 | -43.14 | -264.15 | -83.51 | -381.74 | |
EV to operating cash flow | -35.5 | -35.94 | -191.54 | -490.71 | 635.4 | |
EV to free cash flow | -32.4 | -29.78 | -117.94 | -397.96 | 1.97K | |
Earnings yield | -0.03 | -0.03 | -0.01 | -0.01 | -0.01 | |
Free cash flow yield | -0.03 | -0.03 | -0.01 | 0 | 0 | |
Debt to equity | 0.4 | 0.55 | 0.61 | 0.61 | 0.63 | |
Debt to assets | 0.27 | 0.33 | 0.36 | 0.36 | 0.36 | |
Net debt to EBITDA | 0.14 | -0.42 | -10.4 | -4.82 | -15.34 | |
Current ratio | 6.37 | 3.74 | 3.19 | 3.47 | 3.24 | |
Interest coverage | -97.09 | 668.09 | -18.15 | -54.41 | -28.27 | |
Income quality | 1 | 1 | 1 | 0.16 | -0.26 | |
Dividend Yield | 0.02 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.69 | -0.02 | -0.05 | -0.02 | -0.03 | |
Sales general and administrative to revenue | 1.01 | -1.16 | 0.25 | -0.18 | 1.37 | |
Research and developement to revenue | 0.14 | 0.36 | 0.05 | 0.25 | 0.21 | |
Intangibles to total assets | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | |
Capex to operating cash flow | 0.1 | 0.21 | 0.62 | 0.23 | -0.68 | |
Capex to revenue | -0.2 | -0.69 | -0.2 | -0.05 | -0.13 | |
Capex to depreciation | -0.6 | -1.56 | -1.16 | -0.15 | 0.23 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.55 | 2.29 | 0.99 | 1.38 | 0.95 | |
ROIC | -0.06 | -0.07 | -0.01 | -0.03 | -0.02 | |
Return on tangible assets | -0.06 | -0.07 | -0.01 | -0.03 | -0.02 | |
Graham Net | 0.7 | 0.44 | 0.41 | 0.34 | 0.27 | |
Working capital | 960.58M | 829.62M | 812.56M | 751.6M | 736.96M | |
Tangible asset value | 1.16B | 1.02B | 998.15M | 949.39M | 924.22M | |
Net current asset value | 546.13M | 411.72M | 387.25M | 319.28M | 297.21M | |
Invested capital | 0.4 | 0.55 | 0.61 | 0.61 | 0.63 | |
Average receivables | 166.38M | 126.86M | 109.98M | 99.66M | 80.2M | |
Average payables | 49.66M | 58.25M | 69.37M | 69.21M | 75.69M | |
Average inventory | 44.62M | 47.26M | 57.11M | 57.07M | 58.78M | |
Days sales outstanding | 264.45 | 246.13 | 142.3 | 189.53 | 183.56 | |
Days payables outstanding | 181.89 | 173.59 | 236.15 | 199.28 | 351.42 | |
Days of inventory on hand | 164.97 | 128.36 | 212.63 | 147.78 | 282.44 | |
Receivables turnover | 0.34 | 0.37 | 0.63 | 0.47 | 0.49 | |
Payables turnover | 0.49 | 0.52 | 0.38 | 0.45 | 0.26 | |
Inventory turnover | 0.55 | 0.7 | 0.42 | 0.61 | 0.32 | |
ROE | -0.08 | -0.11 | -0.02 | -0.04 | -0.03 | |
Capex per share | -0.01 | -0.03 | -0.02 | 0 | -0.01 |
603669.SS Frequently Asked Questions
What is Lionco Pharmaceutical Group Co.,Ltd. stock symbol ?
Lionco Pharmaceutical Group Co.,Ltd. is a CN stock and trading under the symbol 603669.SS
What is Lionco Pharmaceutical Group Co.,Ltd. stock quote today ?
Lionco Pharmaceutical Group Co.,Ltd. stock price is $4 today.
Is Lionco Pharmaceutical Group Co.,Ltd. stock public?
Yes, Lionco Pharmaceutical Group Co.,Ltd. is a publicly traded company.